Mechanism of Action
T-Cell Differentiation
Thymopentin acts on immature thymocytes and peripheral T-cell precursors, promoting their differentiation into mature CD4+ and CD8+ T-lymphocyte populations. The peptide binds to thymopoietin receptors on lymphoid progenitor cells, triggering intracellular signaling that drives T-cell maturation and functional specialization.
Immune Balance Restoration
TP-5 preferentially stimulates T-helper (Th1) responses and natural killer (NK) cell activity while moderating Th2 predominance. In immunodeficient states, this restores the CD4/CD8 ratio and augments cellular immunity. In autoimmune contexts, TP-5 may normalize dysregulated immune responses through regulatory T-cell induction.
Research Summary
HIV and Immunodeficiency
HumanSeveral clinical studies in HIV-positive patients before antiretroviral era showed TP-5 preserved CD4 counts and reduced opportunistic infections. While superseded by ART, these trials established TP-5's capacity to support T-cell compartment recovery in immunodeficient individuals.
Autoimmune Conditions
HumanRheumatoid arthritis trials conducted primarily in Italy and Eastern Europe showed TP-5 reduced inflammatory markers and joint symptom scores. Some lupus and psoriasis studies reported immune normalization with TP-5 treatment, though results were mixed across trials.
Cancer Adjunct
HumanPilot studies examined TP-5 as immune support during chemotherapy to reduce immunosuppression and improve recovery. Results suggested potential benefit for maintaining lymphocyte counts but larger confirmatory trials were not completed.
Calculate your Thymopentin dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Immune support | 50 mg | 3x/week x 6 weeks | Subcutaneous |
| Autoimmune modulation | 50 mg | Daily x 4 weeks | Intramuscular |
| Chronic infection support | 50 mg | 3x/week x 8-12 weeks | Subcutaneous |
Doses reflect historical clinical trial parameters; protocols vary by indication.
Interactions
Safety Profile
Thymopentin has a well-established safety record from decades of clinical use in Europe and Asia. Common effects are limited to mild injection site reactions. No significant systemic toxicity has been reported. The very short plasma half-life (~30 seconds) limits systemic exposure. TP-5 is well tolerated across diverse patient populations including elderly and immunocompromised individuals.
References
- [1]Audhya T, et al. Thymopentin: a synthetic peptide with full immunomodulatory activity of thymopoietin. Arch Biochem Biophys. 1986.
- [2]Ramelli F, et al. Thymopentin in HIV infection. Int J Immunopharmacol. 1992.
- [3]Prete GD, et al. Treatment of rheumatoid arthritis with thymopentin. Clin Exp Immunol. 1989.